AlloDx was awarded Shanghai’s “High-tech Enterprise” certification
Recently, Shanghai AlloDx Technology Co., Ltd. successfully passed the relevant regulations on the recognition of high-tech enterprises in the "High-tech Enterprise Recognition Management Measures", "High-tech Enterprise Recognition Management Work Guidelines" and "Shanghai High-tech Enterprise Recognition Management Implementation Measures", and plans to be recognized as the first batch of Shanghai high-tech enterprises in 2020.
Recently, Shanghai AlloDx Technology Co., Ltd. successfully passed the relevant regulations on the recognition of high-tech enterprises in the "High-tech Enterprise Recognition Management Measures", "High-tech Enterprise Recognition Management Work Guidelines" and "Shanghai High-tech Enterprise Recognition Management Implementation Measures", and plans to be recognized as the first batch of Shanghai high-tech enterprises in 2020.
High-tech enterpriseIt refers to a resident enterprise that has been registered in China (excluding Hong Kong, Macao, and Taiwan) for more than one year within the "high-tech fields supported by the state" and continues to conduct research and development and transformation of technological achievements to form the core independent intellectual property rights of the enterprise, and carry out business activities based on this. It is a knowledge-intensive and technology-intensive economic entity. This successful selection as a national high-tech enterprise is not only a powerful explanation of our company's long-term persistence in technological innovation, but also represents our company's technological research and development capabilities for independent innovation.
AllDxAt the beginning of its establishment, it focused on the research and development of new generation molecular diagnostic technology and its clinical transformation in the field of organ transplantation. Currently, it hastransplant liquid biopsyDirection has successfully developed a number of clinical testing products and has11 core invention patents. Next, AlloDx will continue to introduce high-quality talents to provide a fundamental guarantee for independent innovation; continue to increase investment in scientific research, consolidate the development potential of corporate innovation, continue to promote the accuracy of post-operative testing of Chinese transplant patients, and provide each patient with comprehensive and accurate molecular-level information to assist doctors in precise treatment.
